<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04119973</url>
  </required_header>
  <id_info>
    <org_study_id>009</org_study_id>
    <nct_id>NCT04119973</nct_id>
  </id_info>
  <brief_title>A Multicenter Prospective Study of Application of Platelet Mapping in Acute-on-chronic-liver Failure in China</brief_title>
  <official_title>A Multicenter Prospective Study of Application of Platelet Mapping in Acute-on-chronic-liver Failure in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Southwest Hospital, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Hospital of Jilin University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Xinjiang Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mengchao Hepatobiliary Hospital of Fujian Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Taihe Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nanfang Hospital of Southern Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ineffective hemostasis or a paradoxical prothrombotic state of Acute-on-chronic liver disease
      (ACLF) has been well established. Thrombelastography measures the dynamics of thrombin
      production and provides a global assessment of coagulation incorporating the cumulative
      effect of the interactions at various levels between plasma components and cellular component
      of coagulation. And through the platelet mapping, it can help provide a picture of patients'
      function of platelet. Based on the primary result of our derivation cohort(NCT03281278), ACLF
      patients with high ADP inhibition rate had high 28-day mortality.This multicenter validation
      cohort aims to validate the predictive role of platelet mapping in ACLF prognosis, organ
      failure developments and short term mortality.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 16, 2018</start_date>
  <completion_date type="Actual">November 4, 2019</completion_date>
  <primary_completion_date type="Actual">August 4, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>28-day mortality</measure>
    <time_frame>28-day</time_frame>
    <description>death within 28-day</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>28-day progression</measure>
    <time_frame>28-day</time_frame>
    <description>progressed to EASL defined ACLF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>90-day mortality</measure>
    <time_frame>90-day</time_frame>
    <description>death within 90-day</description>
  </secondary_outcome>
  <enrollment type="Actual">486</enrollment>
  <condition>Thrombelastography</condition>
  <condition>Acute on Chronic Liver Failure</condition>
  <condition>Platelet</condition>
  <condition>Multicenter Prospective Study</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>standard treatment</intervention_name>
    <description>standard medical treatment</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with ACLF regardless of aetiology, International Normalized Ratio (INR)≥1.5 and
        total bilirubin≥85μmol/L
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  INR≥1.5 and total bilirubin≥85μmol/L

        Exclusion Criteria:

          -  INR≤1.5 or total bilirubin≤85μmol/L;

          -  those who had hepatocellular carcinoma or other types of malignancies;

          -  obstructive biliary diseases or other disease lead to bilirubin evaluation;

          -  those who had acute hemorrhage one week before admission

          -  those who received platelet, cryo transfusion or plasmapheresis one week before
             admission

          -  pregnancy and breastfeeding

          -  those who received liver transplantation or kidney transplantation;

          -  combine with other disease lead to organ failure including heart failure (NYHA
             IV),respiratory failure（PaO2&lt;60mmHg),renal insufficiency(CKD 5) and conscious
             disturbance (GCS&lt;8)

          -  readmission;

          -  death within 24 hours.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hepatology Unit, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>October 7, 2019</study_first_submitted>
  <study_first_submitted_qc>October 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2019</study_first_posted>
  <last_update_submitted>January 6, 2020</last_update_submitted>
  <last_update_submitted_qc>January 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Thrombelastography</keyword>
  <keyword>Acute on Chronic Liver Failure</keyword>
  <keyword>Platelet</keyword>
  <keyword>Multicenter Prospective Study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>Hepatic Insufficiency</mesh_term>
    <mesh_term>End Stage Liver Disease</mesh_term>
    <mesh_term>Acute-On-Chronic Liver Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

